Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999-2018. Kaplan HG, Malmgren JA, Guo B, Atwood MK, et al. Breast Cancer Res Treat 2022 Jul 22. pii: 10.1007/s10549-022-06678.

Read + Share

Amedeo Smart

Independent Medical Education

Kaplan HG, Malmgren JA, Guo B, Atwood MK, et al. Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999-2018. Breast Cancer Res Treat 2022 Jul 22. pii: 10.1007/s10549-022-06678.
PMID: 35869377